Mariano Facundo Werner Reyes, Presenter: Nothing to Disclose

Carmen Sebastia Cerqueda MD, Abstract Co-Author: Nothing to Disclose

Blanca Pano Brufau MD, Abstract Co-Author: Nothing to Disclose

Begona Mellado, Abstract Co-Author: Nothing to Disclose

Oscar Reig, Abstract Co-Author: Nothing to Disclose

Carlos Nicolau MD, Abstract Co-Author: Nothing to Disclose

- To review the new treatment algorithms based on targeted antiangiogenic therapy for metastatic renal cell carcinoma (mRCC). - To describe specific radiological findings of side effects resulting from these new treatments. - To depict typical and atypical responses and relapse patterns in follow-up by means of CT and MR, including functional techniques.  

1- Targeted angiogenic therapies in mRCC; specific pathways. 2- Targeted mRCC antiangiogenic therapies, guidelines and clinical trial reviews. 3- Secondary effects of targeted antiangiogenic therapies; review of each specific therapy with radiological examples. 4- Pitfalls of RECIST in the monitoring of mRCC targeted antiangiogenic therapy. 5- New criteria assessment of therapeutic response of these therapies based on density and perfusion. Review of qualitative signs and quantitative parameters. 6- Does diffusion play a role in the monitoring of these new therapies? 7- Positive and negative prognosis of radiological findings in baseline and follow-up studies. 8- Patterns of response, typical and atypical (based on size, density and perfusion parameters) 9- Patterns of relapse  

http://abstract.rsna.org/uploads/2014/14004097/14004097_h3l3.pdf

Werner Reyes, M, Sebastia Cerqueda, C, Pano Brufau, B, Mellado, B, Reig, O, Nicolau, C, Metastatoc Renal Cell Carcinoma and Targeted Antiangiogenic Therapy: Old Illness, New Concerns.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004097.html